CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients
CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination...
Read MoreCatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation
CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy...
Read MoreCatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance
CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor...
Read MoreCatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody Visugromab in Combination with Nivolumab at ASCO 2023
CatalYm Announces Initial Data from Ongoing Phase 2a Trial Evaluating GDF-15-targeting Antibody...
Read MoreCatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab at the 2023 ASCO Annual Meeting
CatalYm to Present Early Phase 2a Data on GDF-15 Neutralizing Antibody Visugromab...
Read MoreCatalYm Expands Visugromab Development Based on Positive Early Phase 2 Data in Two Indications and Adds Confirmatory Response-Predictive Biomarker Cohort
CatalYm Expands Visugromab Development Based on Positive Early Phase 2 Data in...
Read MoreCatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors
CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate...
Read MoreCatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced Cancer Patients into the US
CatalYm Receives FDA IND Clearance to Expand Development of Visugromab in Advanced...
Read MoreCatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for Visugromab and Nivolumab Combination
CatalYm Demonstrates Clinical Efficacy and Tolerability in First-in-Human Phase 1 Trial for...
Read MoreCatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15 Neutralizing Antibody Visugromab (CTL-002) at the 2022 ESMO Congress
CatalYm to Present Complete Phase 1 Safety and Efficacy Data on GDF-15...
Read More